Atlas Trials

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Clinical trial NCT03400033 · COMPLETED

Trial details

NCT number
NCT03400033
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Anaemia
Start date
2018-09-05
Primary completion
2020-06-19
Enrollment
407

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.